Pipe Line

Pipe Line & Other Development Projects

MediWound is developing additional wound care products, which have potential proprietary use in the treatment of soft tissues, as well as additional indications for its currently available product.

The enzymatic technology has proven efficacious in Phase II trials for hard to heal wounds and has shown promise in pre-clinical animal model studies for the orphan connective tissue diseases.


MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)


Read More…